pitavastatin calcium : The calcium salt of pitavastatin. Used for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5282451 |
| CHEMBL ID | 1237061 |
| CHEBI ID | 71258 |
| CHEBI ID | 94569 |
| SCHEMBL ID | 22720 |
| MeSH ID | M0281810 |
| Synonym |
|---|
| nk 104 (acid) |
| iyd54xeg3w , |
| flovas |
| ccris 8652 |
| unii-iyd54xeg3w |
| (+)-monocalciumbis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-hepten |
| pitavastatin calcium |
| redevant |
| alipza |
| livazo |
| itavastatin calcium |
| nks-104 |
| p-872441 |
| 6-heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, calcium salt (2:1), (s-(r*,s*-(e)))- |
| pitavastatin hemicalcium |
| bis((3r,5s,6e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt |
| D01862 |
| pitavastatin calcium (jan) |
| livalo (tn) |
| nk 104 |
| 111GE002 |
| calcium (e,3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate |
| chebi:71258 , |
| pitavastatin calcium salt |
| CHEMBL1237061 |
| dtxsid4046448 , |
| tox21_112195 |
| dtxcid40819916 |
| cas-147526-32-7 |
| pitavastatin calcium [who-dd] |
| pitavastatin calcium [mart.] |
| pitavastatin calcium salt [mi] |
| pitavastatin calcium [orange book] |
| pitavastatin calcium [jan] |
| AM84441 |
| AKOS015900407 |
| bis((3r,5s,6e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate) monocalcium salt |
| calcium bis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate} |
| SCHEMBL22720 |
| KS-1220 |
| RHGYHLPFVJEAOC-FFNUKLMVSA-L |
| calcium (3r,5s,e)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate |
| tox21_303926 |
| NCGC00356953-01 |
| Q-201590 |
| (3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid hemicalcium salt |
| calcium;(e,3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate |
| mfcd01937979 |
| CHEBI:94569 |
| pitavastatin hemicalcium;nk-104 |
| Q27139472 |
| (+)-monocalciumbis[(3r,5s,6e)-7-[2-cyclopropyl-4(4-fluorophenyl)-3-quinolyl]3,5-dihydroxy-6-hepteno ate] |
| 6-heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3r,5s,6e)- |
| calcium (3r,5s,e)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoate |
| pitavastatin calcium (mart.) |
| calcium bis((3r,5s,6e)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate) |
| monocalcium bis((3r,5s,6e)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate) |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| antioxidant | A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| calcium salt | |
| statin (synthetic) | A statin which does not occur naturally and which is not obtained by chemical transformation of a naturally occurring statin. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.4845 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| TDP1 protein | Homo sapiens (human) | Potency | 2.2723 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 2.3807 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 10.3183 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 14.1254 | 0.0123 | 7.9835 | 43.2770 | AID1346984 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 6.5921 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.1014 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401; AID1259403 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 7.9949 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078; AID743080; AID743091 |
| caspase-3 | Homo sapiens (human) | Potency | 10.3183 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.0944 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 5.8024 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 5.8024 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 19.9682 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | IC50 (µMol) | 8.9000 | 0.0000 | 0.7949 | 8.9000 | AID453406 |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.5500 | 0.0009 | 0.2094 | 9.0300 | AID309702 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | Kd | 13.3000 | 0.0004 | 0.5838 | 8.8000 | AID1431666 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1431671 | Activity at Nur77 LBD (unknown origin) expressed in human MCF-7 cells at 10 uM after 24 hrs by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. |
| AID1431666 | Binding affinity to RXRalpha-LBD (unknown origin) measured up to 120 sec by surface plasma resonance method | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. |
| AID1431672 | Antagonist activity at RARgamma (unknown origin) expressed in human MCF-7 cells assessed as inhibition of AHPN induced receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. |
| AID1431675 | Agonist activity at RARgamma (unknown origin) expressed in human MCF-7 cells assessed as increase in AHPN induced receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. |
| AID1431667 | Antagonist activity at Myc-tagged RXRalpha (unknown origin) expressed in human MCF-7 cells assessed as inhibition of 9-cis-RA induced receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. |
| AID309702 | Inhibition of Holtzman-Sprague-Dawley rat liver HMG CoA reductase after 30 mins | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24 | Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolemic agents. |
| AID453406 | Inhibition of HMG CoA reductase by spectrophotometry | 2009 | Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23 | Synthesis and HMG-CoA reductase inhibition of 2-cyclopropyl-4-thiophenyl-quinoline mevalonolactones. |
| AID1431669 | Antagonist activity at Myc-tagged RXRalpha (unknown origin) expressed in human MCF-7 cells assessed as inhibition of 9-cis-RA induced receptor transactivation at 1 uM after 24 hrs by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||